Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well sunitinib malate works in treating
patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
Sunitinib malate may inhibit the ability of cancers to grow blood vessels, something they
need to grow. It may also shrink tumors.